沙培林口服治疗胃癌术后疗效观察

Study on oral administration of OK-432(picibanil) after resection of advanced stomach cancer

目的观察沙培林口服对胃癌术后患者的疗效。方法晚期胃癌术后患者58例,随机分为3组:A组口服沙培林,B组肌肉注射沙培林,C组口服安慰剂。分别观察和计算患者细胞免疫水平及生存率。结果沙培林口服组和肌肉注射组T细胞亚群CD3+、CD4+、CD4+/CD8+和NK水平均高于安慰剂组,而口服组和注射组之间差异无显著性。口服沙培林可能会延长患者生存期,口服沙培林无发热等不良反应。结论沙培林口服可提高胃癌术后患者的免疫力,并可能延长患者生存期,沙培林口服方便,副反应小,值得临床扩大试验。

Objective To study oral administration of OK-432 （plclbanil） in cases with resected stomach cancer. Methods Fifty-eight cases with resected stomach cancer were random divided into 3 groups： oral administration （ A）, intramuscular injection （ B ） and placeboes （ C ）. The cellular immuninty and survival time of the patients were investigated. Results The levels of CD3 ^＋ , CD4^＋ , CIM ^＋/CD8^＋ and NK in group A and B were higher than that in group C, and there is statistic signifance. But there is no statistic significance between A and B. Oral administration of OK-432 might prolong the survival time of patients ,and it has no side effects, such as fever, allergy. Conclusion Oral administration of OK-432 may improve immunity of the patients after resection of advanced stomach cancer, and might prolong the survival time of pa tients. It is worthy of clinically widely use.